Details for Patent: 8,147,809
Which drugs does patent 8,147,809 protect, and when does it expire?
Patent 8,147,809 protects SOFDRA and is included in one NDA.
This patent has ten patent family members in six countries.
Summary for Patent: 8,147,809
| Title: | Soft anticholinergic esters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Soft anticholinergic esters of the formulas: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Nicholas S. Bodor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Bodor Laboratories Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/494,367 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Compound; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 8,147,809: Claim Scope, Patent Landscape, Exclusivity and Generic-Entry RiskU.S. Patent No. 8,147,809 covers a narrow class of quaternary pyrrolidinium bromide anticholinergic compounds, stereoisomeric forms of those compounds, and pharmaceutical compositions containing them. The strongest protection is compound-specific: a product containing one of the expressly listed salts may fall within claims 1-3 even if it is formulated differently. Claims 4-6 extend protection to pharmaceutical compositions but are secondary to the underlying compound claims. The claims do not, by themselves, establish an FDA-approved product, an Orange Book listing, an approved drug name, or a current commercial product. The patent text supports a chemical and formulation analysis, but a definitive expiration date, terminal disclaimer analysis, continuation-family review, Orange Book status, and litigation assessment require the complete USPTO prosecution and family records. What compounds does U.S. Patent 8,147,809 protect?The patent protects anticholinergic pyrrolidinium bromide compounds built around four structural elements:
The claimed compounds contain one or more stereogenic centers. The claims expressly cover individual stereoisomers and, in several instances, mixtures of stereoisomers.
The use of a quaternary pyrrolidinium center is significant. Unlike a neutral or readily protonatable tertiary amine, the claimed compounds carry a permanent positive charge. That structural feature can affect receptor distribution, absorption, inhalation delivery, systemic exposure and formulation strategy. A competitor cannot avoid the claims merely by changing a dosage form if the active chemical compound remains within the claimed structure. How broad is claim 1?Claim 1 is the principal genus claim. It covers a compound defined by a formula in which R is methyl or ethyl, with the indicated stereochemical configurations at each marked chiral center. Its scope has three important dimensions. R-group coverageThe claim covers two alternatives:
A compound with a propyl, isopropyl or other homologous group would not literally satisfy the R limitation as stated. Such a compound could raise a doctrine-of-equivalents issue, but that would depend on prosecution history, structural differences and the specific accused product. Stereochemical coverageClaim 1 is materially broader than a single enantiomer claim. It covers compounds having the R, S or RS configuration at each marked chiral center, or mixtures of those configurations. This language potentially reaches:
The claim therefore reduces a common design-around route. A competitor cannot necessarily avoid claim 1 by using a different stereochemical form of the same constitutional structure. Salt and charge-state limitationsThe claim language in claims 2 and 3 expressly identifies the bromide salts. Claim 1, as supplied, refers to a formula rather than repeating the full chemical name. The applicable Markush and structural limitations must be read from the issued patent drawings and specification. On the supplied claim text, a materially different counterion should not automatically be assumed to fall within the claim. A chloride, iodide, methanesulfonate or fumarate salt may create a non-infringement position if the bromide counterion is a claim limitation. The strength of that position depends on whether the issued claim defines the counterion expressly, incorporates it through the depicted formula, or covers the cation independently. What compounds are expressly listed in claims 2 and 3?Claims 2 and 3 narrow the invention to named compounds and selected stereochemical forms.
Claims 2 and 3 are compositionally important because they create fallback positions if claim 1 is rejected or invalidated. A challenger may attack the genus claim for written-description, enablement, anticipation or obviousness reasons while leaving one or more individually claimed stereoisomers intact. The expressly listed structures include both methyl and ethyl ester variants. Claim 2 also identifies multiple configurations at the 2-position and at the additional stereocenters designated in the claim. The presence of separate stereochemical limitations suggests that the patent family placed commercial or pharmacological value on particular isomers rather than treating all forms as interchangeable. What pharmaceutical compositions are protected?Claims 4-6 cover pharmaceutical compositions containing an anticholinergically effective amount of a claimed compound and a non-toxic pharmaceutically acceptable carrier. These claims have two principal limitations:
The claims do not, based on the supplied text, require a particular:
This makes the composition claims potentially broad across dosage forms, but their enforceability depends on proving that the accused composition contains a claimed compound in an effective amount. A formulation patent covering particle engineering, device architecture, excipient ratios or a specific inhaled dose would be separate from these basic composition claims. Does the patent protect methods of treatment?The supplied claims do not include a method-of-treatment claim. They are directed to:
That distinction matters in the United States. A product may infringe a compound or composition claim regardless of the therapeutic indication appearing on its label. Conversely, a competitor might avoid a method-of-use patent by changing the indication or dosing regimen, but that strategy does not avoid a structurally applicable compound claim. The absence of an identified method-of-use claim in the supplied claims also means the patent does not, on this record, provide distinct protection for:
Those subjects may be covered by other patents in the family or by unrelated patents, but they are not established by claims 1-6. How strong is the patent estate based on the issued claims?The patent has a mixed but commercially meaningful claim structure. Strong pointsThe compound claims have several characteristics that can support enforcement:
A generic or follow-on company that uses the same active moiety would face a substantial chemical infringement risk if the product contains the claimed bromide compound or converts to that compound during manufacture or administration. Limiting pointsThe patent does not appear, from the supplied claims, to cover every anticholinergic compound with a related pharmacophore. Design-around opportunities may include:
A design-around must be assessed against the complete claim language, not only the chemical name. A prodrug or alternate salt can still create infringement risk if the claimed compound is made during synthesis, exists in the administered product, or is generated in vivo under an applicable infringement theory. What is the likely patent expiration date?U.S. Patent No. 8,147,809 issued on April 3, 2012. The controlling term is generally 20 years from the earliest effective nonprovisional U.S. filing date or applicable international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and statutory exceptions under 35 U.S.C. §§ 154 and 156. The issued patent number and claims alone do not establish the final enforceable expiration date. A reliable term calculation must account for:
The key commercial point is that U.S. 8,147,809 should not be treated as the entire exclusivity position. A product may remain protected after this patent expires through later-filed patents covering a specific stereoisomer, formulation, inhaler, dosage regimen, manufacturing process or combination product. What is the Orange Book status of U.S. Patent 8,147,809?The supplied claims do not identify an FDA-approved product or application number. The patent therefore cannot be assigned an Orange Book status solely from the claim language. For an approved small-molecule drug, Orange Book relevance depends on whether the patent is submitted by the NDA holder and accepted by FDA as claiming:
FDA does not list every patent that may theoretically read on an approved product. Orange Book listing is tied to the statutory patent-submission framework in 21 U.S.C. § 355(b)(1) and FDA regulations. If no approved product is associated with the claimed compounds, there would be no product-specific Orange Book listing and no Hatch-Waxman Paragraph IV dispute based on this patent. If an approved product is associated with the compounds, the listing status must be checked against the current FDA Orange Book and the relevant NDA patent-certification history.[1] Are there Paragraph IV challenges or generic litigation?The supplied information does not establish a Paragraph IV certification, Abbreviated New Drug Application, district-court action, or settlement involving U.S. 8,147,809. A Paragraph IV case requires an ANDA applicant to certify that a listed patent is invalid, unenforceable or will not be infringed. The resulting litigation ordinarily depends on four facts:
A patent that is not Orange Book-listed can still be asserted in ordinary patent litigation, but it does not automatically create the Hatch-Waxman 30-month stay associated with a listed patent. What manufacturing and intellectual-property barriers does the patent create?The patent creates a direct barrier where a competing manufacturer must synthesize one of the claimed compounds. Relevant risk points include:
A supplier may avoid literal infringement by using a different synthetic route, but process changes do not avoid a claim directed to the final compound. Conversely, a process patent could create separate manufacturing risk even when the final active ingredient falls outside U.S. 8,147,809. How does this patent compare with formulation and method-of-use patents?U.S. 8,147,809 is primarily a chemical compound patent.
A competitor that avoids a formulation or use patent may still infringe the compound claims. The reverse is also true: expiration or invalidity of the compound patent does not eliminate separate formulation, device or process patents. What generic launch scenarios exist?Launch after complete patent expiryThis is the lowest-risk scenario if no continuation, formulation, method-of-use or regulatory exclusivity remains. The entrant would still need to address applicable FDA requirements and any other enforceable patents. Paragraph IV launchIf the patent is Orange Book-listed, an ANDA applicant could challenge validity, enforceability or infringement. The commercial risk would include litigation, a possible 30-month stay and potential damages for an at-risk launch. Non-infringing design-aroundA competitor could develop a structurally distinct anticholinergic compound, alternate salt, different ring system or different ester architecture. This route carries development and regulatory risk because pharmacology, delivery and clinical comparability may change. Authorized or licensed entryA license, covenant not to sue or settlement could permit earlier market entry. No such agreement is established by the supplied claims. What geographic coverage does the patent provide?U.S. Patent 8,147,809 provides rights only in the United States. Foreign counterparts, if any, must be evaluated separately by jurisdiction. Important differences include:
A U.S. expiration or invalidity event does not automatically affect counterpart patents in Europe, Canada, Japan, China or other markets. Key Takeaways
FAQsDoes changing bromide to chloride avoid U.S. Patent 8,147,809?Not necessarily. If the issued claim requires the bromide salt, a different counterion may support a non-infringement position. The complete claim language and prosecution history determine whether the cation, salt or both are required. Does using only one enantiomer avoid the patent?Usually not if the selected enantiomer is one of the stereochemical configurations expressly covered. Claim 1 also covers specified stereoisomers and mixtures. Can a different inhaler avoid the patent?A different inhaler may avoid a device-specific patent, but it does not avoid a compound claim if the inhaler contains a claimed active ingredient. Is a pharmaceutical composition claim limited to inhaled products?Not on the supplied language. Claims 4-6 refer generally to a pharmaceutical composition and a pharmaceutically acceptable carrier. They do not identify an inhaled dosage form. Can a generic manufacturer challenge this patent without filing Paragraph IV?Yes. A company can pursue non-infringement or invalidity strategies outside the ANDA Paragraph IV framework, although the procedural and commercial consequences differ from a Hatch-Waxman challenge. References
More… ↓ |
Drugs Protected by US Patent 8,147,809
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,147,809
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E529399 | ⤷ Start Trial | |||
| Austria | E529400 | ⤷ Start Trial | |||
| Australia | 2006315657 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
